NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. At the end of 2025, the company has two products in clinical development (NFL-101 and NFL-102) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol addiction).

Employees

Sector

Biotechnology & Medical Research

Calendar

22/10 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change
29/26/29	€0.8310	-3.03%
27/26/27	€0.8570	+4.26%
26/26/26	€0.8220	-0.36%
25/26/25	€0.8250	-6.14%
24/26/24	€0.8790	+9.60%

Delayed Quote Börse Stuttgart

More quotes

Annual profits - Rate of surprise

Company calendar

Delayed Börse Stuttgart 12:31:59 29/08/2026 am IST			5-day change	1st Jan Change
0.8310 ^EUR	-3.03%		+0.59%	-19.61%

28/07	NFL Biosciences Submits Application For Authorization Of The Phase 2 Tonic Clinical Trial Evaluating NFL-102 In Smoking Cessation	CI
07/07	Nfl Biosciences Presents Three Scientific Communications on Nfl-101 and Nfl-102 At 2026 Srnt-Europe Conference	CI

Market Cap	1.17Cr 1.35Cr 1.09Cr 99.78L 1.88Cr 129.31Cr 1.89Cr 13Cr 5.06Cr 65Cr 5.08Cr 4.97Cr 216.44Cr	P/E 2024	-9.56x	P/E 2025	-4.62x
Enterprise Value	1Cr 1.17Cr 94.13L 85.92L 1.62Cr 111.35Cr 1.62Cr 11Cr 4.36Cr 56Cr 4.37Cr 4.28Cr 186.37Cr	EV / Sales 2024	3,70,592x	EV / Sales 2025	70,790x
Free-Float	85.79%	Yield 2024 *	-	Yield 2025	-

28/07	NFL Biosciences Submits Application For Authorization Of The Phase 2 Tonic Clinical Trial Evaluating NFL-102 In Smoking Cessation	CI
07/07	Nfl Biosciences Presents Three Scientific Communications on Nfl-101 and Nfl-102 At 2026 Srnt-Europe Conference	CI
30/06	NFL Biosciences Successfully Manufactures GMP Clinical Batch Of NFL-102 And Validates Industrial Production Chain	CI
30/06	NFL Biosciences validates industrial-scale production of NFL-102 for smoking cessation
02/06	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	CI
01/06	NFL Biosciences validates breakthrough in personalized medicine
26/05	Glimmers of hope for Middle East peace grow brighter
26/05	NFL Biosciences to File Patent Application for Smoking Cessation Drug-linked Biomarker	MT
25/05	NFL Biosciences files new patent application
25/05	NFL Biosciences Files Patent Application Protecting Predictive Efficacy Biomarker Associated With NFL-101	CI
12/05	NFL Biosciences SA Clarifies Objectives And Evaluation Criteria For Predictive Biomarker Associated With NFL-101	CI
04/05	NFL Biosciences Presents Work On NFL-102 For Smoking Cessation At International Scientific Conferences	CI
16/04	NFL Biosciences SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI

20/25/20	Nfl Biosciences Outlines Its Development Plan for Nfl-101 in Smoking Cessation Following Receipt of Scientific Advice from Several European Agencies and the U.S. Fda	CI
02/24/02	NFL Biosciences: Invest Securities reduces its target
15/24/15	NFL Biosciences: Invest Securities raises its target

NFL Biosciences Share Price Börse Stuttgart

Stocks

82F

FR0014003XT0

Biotechnology & Medical Research

Valuation : NFL Biosciences

Chart: NFL Biosciences

Latest news : NFL Biosciences

Analysts' recommendations : NFL Biosciences

Press Releases : NFL Biosciences

News in other languages : NFL Biosciences

Quotes and Performance

Price Extremes

Managers and Directors : NFL Biosciences

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

28/07	NFL Biosciences Submits an Application for Authorization of the Phase 2 TONIC Clinical Trial Evaluating NFL-102 in Smoking Cessation	BU
07/07	International Scientific Recognition for NFL Biosciences: 3 Presentations Selected at the 2026 SRNT-Europe Conference, Including an Oral Presentation on NFL-102	BU
30/06	NFL Biosciences Announces the Successful Manufacturing of a GMP Clinical Batch of NFL-102 and Validates Its Industrial Production Chain	BU
01/06	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	BU
25/05	NFL Biosciences Is Strengthening Its Personalized Medicine Approach to Smoking Cessation With a New Patent Application	BU

28/07	NFL Biosciences dépose la demande d'autorisation de l'étude clinique de phase 2 TONIC évaluant NFL-102 dans le sevrage tabagique
07/07	NFL Biosciences : Bilan semestriel du contrat de liquidité
07/07	Reconnaissance scientifique internationale pour NFL Biosciences : 3 présentations retenues au congrès SRNT-Europe 2026, dont une communication orale sur NFL-102
30/06	NFL Biosciences valide la production industrielle du NFL-102 contre la tabagisme
30/06	NFL Biosciences annonce la fabrication avec succès d’un lot clinique GMP de NFL-102 et valide sa chaîne industrielle de production

1 week	+0.59%
Current month	+9.31%
1 month	+10.44%
3 months	+3.63%
6 months	-24.43%
Current year	-19.61%

Manager	Title	Age	Since
Bruno Lafont CEO	Chief Executive Officer	-	17/10/2024
Guillaume Audema DFI	Director of Finance/CFO	-	-
Violaine Desort Henin CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Ignacio Faus CHM	Chairman	-	27/02/2023
Bruno Lafont CHM	Chairman	-	17/10/2024
Francis Ahner BRD	Director/Board Member	-	19/05/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NFL BIOSCIENCES	-3.03%	+0.59%	-36.04%	-68.84%	1.36Cr
WUXI APPTEC CO., LTD.	-1.59%	-6.25%	+64.99%	+99.09%	7.06TCr
ARGENX SE	-1.34%	-0.75%	+48.56%	+90.63%	6.61TCr
BIONTECH SE	-7.68%	-12.17%	+0.44%	-15.16%	2.8TCr
INSMED INCORPORATED	-2.33%	-6.02%	-12.43%	+446.69%	2.65TCr
WUXI BIOLOGICS (CAYMAN) INC.	+0.30%	+2.03%	+59.48%	+14.21%	2.64TCr
PHARMAESSENTIA CORPORATION	-0.96%	+12.36%	+280.38%	+439.54%	2.04TCr
GENMAB A/S	-0.51%	+0.23%	+33.71%	-18.02%	2.02TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.91%	-3.47%	+11.03%	+508.52%	1.6TCr
EXELIXIS, INC.	-1.41%	+0.35%	+43.19%	+144.68%	1.37TCr
Average	-1.96%	+1.12%	+49.33%	+164.13%	3.2TCr
Weighted average by Cap.	-1.93%	+1.23%	+56.34%	+151.08%

	2024	2025
Net sales	46 53.38 43.13 39.37 74.17 5.1T 74.41 511.7 199.65 2.58T 200.43 196.06 8.54T	188 218.17 176.27 160.91 303.13 20.85T 304.09 2.09T 815.95 10.53T 819.13 801.31 34.9T
Net income	-20.81L -24.15L -19.51L -17.81L -33.55L -23Cr -33.66L -2.31Cr -90.31L -12Cr -90.66L -88.69L -39Cr	-33.18L -38.5L -31.11L -28.4L -53.5L -37Cr -53.67L -3.69Cr -1.44Cr -19Cr -1.45Cr -1.41Cr -62Cr
Net Debt	-20.73L -24.05L -19.43L -17.74L -33.42L -23Cr -33.52L -2.31Cr -89.95L -12Cr -90.3L -88.34L -38Cr	-16.19L -18.79L -15.18L -13.86L -26.11L -18Cr -26.19L -1.8Cr -70.29L -9.07Cr -70.56L -69.02L -30Cr

1 week	0.8	0.93
1 month	0.76	0.93
3 years	0.75	3.06
5 years	0.56	4.43